問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Veterans General Hosptial (在職)

Division of Rheumatology

Division of General Internal Medicine

Taipei Veterans General Hospital

Division of Rheumatology

更新時間：2023-09-19

曾瑞成
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曾瑞成

Kaohsiung Veterans General Hosptial

Division of Rheumatology

List

41Cases

2015-09-01 - 2018-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

羅淑芬
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2015-10-15 - 2020-06-30

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

  • Condition/Disease

    Active Systemic Lupus Erythematosus

  • Test Drug

    STELARA

Participate Sites
6Sites

Terminated4Sites

Study ended1Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

藍忠亮
China Medical University Hospital

2010-06-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2015-08-01 - 2017-07-31

Phase III

A randomized, double-blind, placebo-controlled confirmatory study of the safety and efficacy of ASP015K in patients with rheumatoid arthritis (RA) who had an inadequate response to DMARDs

  • Condition/Disease

    rheumatoid arthritis (RA) who had an inadequate response to DMARDs

  • Test Drug

    ASP015K

Participate Sites
11Sites

Terminated10Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

蔡文展
Kaohsiung Municipal Gangshan Hospital

未分科

2016-10-01 - 2020-03-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2008-03-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2007-05-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2018-11-01 - 2022-04-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Baricitinib

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2020-06-01 - 2022-01-31

Phase III

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    Baricitinib

Participate Sites
9Sites

Recruiting9Sites

2011-02-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB